Лучшие больницы для «Atrioventricular Canal Defect» в Хайдарабад, Индия

In India, the total cost of complete Atrioventricular Canal Defect (AVCD) repair at a JCI- or NABH-accredited hospital typically ranges from USD 5,000 to USD 9,000. This estimate is all-inclusive and covers the cardiac surgery itself, cardiopulmonary bypass perfusion charges, the Pediatric Cardiac Intensive Care Unit (PCICU) stay of 3–5 days, the step-down ward stay of 7–11 days, standard postoperative medications (including inhaled nitric oxide charges, milrinone infusion, diuretics, and ACE inhibitors), and routine inpatient investigations such as echocardiography, ECG, and chest X-rays. In the UAE — specifically Dubai and Abu Dhabi — the equivalent procedure at a JCI/DHA-accredited hospital is estimated to cost between USD 14,000 and USD 22,000, reflecting the higher operating cost environment and premium hospital infrastructure. India is therefore approximately 40–60% less expensive than the UAE for this procedure. Neither estimate includes international airfare, accommodation for accompanying family members during the post-discharge observation period, or additional interventions that may be required for complex cases (such as pulmonary artery banding prior to complete repair, or permanent pacemaker implantation). GAF Healthcare provides a detailed, personalized cost estimate after review of the child's medical records, as complexity factors such as Rastelli valve type, degree of pulmonary hypertension, and associated cardiac lesions can influence the final cost.

International air travel should not be attempted before a minimum of 4 to 6 weeks from the date of surgery for Atrioventricular Canal Defect repair. This timeline is not arbitrary — it reflects several specific medical safety thresholds that must be met before a pediatric cardiac patient can safely tolerate the physiological stresses of flight, including cabin altitude pressurization (equivalent to approximately 6,000–8,000 feet above sea level), limited access to emergency medical care, and prolonged immobility. Before a fit-to-fly clearance is issued, the treating pediatric cardiologist and surgeon must confirm: (1) sternal bone healing is adequate, assessed clinically and radiographically; (2) a repeat echocardiogram shows a stable repair with no significant residual ventricular septal defect, no significant left atrioventricular valve regurgitation, and no pericardial or pleural effusion; (3) oxygen saturation at rest is acceptable without supplemental oxygen; (4) the child is tolerating full oral feeds and has demonstrated adequate weight gain; and (5) all cardiac medications are stable, with no recent changes requiring close monitoring. Patients who developed complications such as postoperative pulmonary hypertension, chylothorax, or transient complete heart block may require a longer stay of 6–8 weeks or more. GAF Healthcare's case manager tracks all follow-up appointments during the post-discharge period and ensures the family receives the formal fit-to-fly letter from the treating team before departure arrangements are confirmed.

At high-volume pediatric cardiac centers in India and the UAE — the types of centers to which GAF Healthcare refers patients — the operative survival rate for complete Atrioventricular Canal Defect (AVCD) repair is 92–96%, meaning that 92 to 96 out of every 100 children undergoing the procedure survive the surgical episode and the immediate postoperative period. Partial AVCD repair carries an even lower operative risk, with survival rates exceeding 98–99% at experienced centers. These figures are consistent with outcomes published in the Society of Thoracic Surgeons (STS) Congenital Heart Surgery Database and peer-reviewed literature from leading international pediatric cardiac programs. Success rates are most strongly influenced by three factors: (1) the volume of congenital cardiac surgery performed at the center — centers performing more than 150–200 congenital open-heart operations annually consistently demonstrate superior outcomes; (2) preoperative pulmonary vascular resistance — children repaired before the development of significant pulmonary hypertension (PVR index <4 Wood Units·m²) have substantially better outcomes than those repaired later; and (3) the degree of left atrioventricular valve regurgitation at the end of repair, assessed by intraoperative transesophageal echocardiography. Long-term freedom from reoperation (most commonly for recurrent left AV valve regurgitation) is approximately 85–90% at 10 years. Children with trisomy 21 undergoing complete AVCD repair achieve operative survival rates equivalent to chromosomally normal children, a finding consistently reproduced across multiple international series.